All In Biotech

Drug Trial Radar · NCT05288023

Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)

Azithromycine Pour la Vie Des Enfants au Niger - Implémentation et Recherche: Essai mortalité et résistance (Azithromycin for Child Survival in Niger: Programmatic Trial)

Last checked: Nov 19, 2026Latest source record: Mar 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 169,707 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

169,707

Actual

Start

Dec 1, 2022

Primary completion

Jan 15, 2024

Study completion Jan 15, 2024

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bill and Melinda Gates Foundation; Ministry of Health, Niger
First posted
Mar 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 month
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The MORDOR trial found that biannual distribution of azithromycin to children 1-59 months old reduced child mortality. The World Health Organization (WHO) released conditional guidelines for this intervention, which include targeting azithromycin distributions to children 1-11 months of age in high mortality settings. The proposed trial aims to demonstrate and evaluate large-scale implementation of azithromycin to children aged 1-11 months old in the context of a programmatic setting while monitoring mortality and resistance antimicrobial resistance.

Conditions

  • Resistance Bacterial
  • Morality
  • Child Health
  • Implementation

Interventions

  • Azithromycin for Oral SuspensionDrug

    Azithromycin will be administered as a single dose in oral suspension form for children (up to the maximum adult dose of 1g). Dosage will be calculated by age for children aged 1-5 months. For children 6-59 months of age, height-based dosing will be used via height-stick approximation as currently performed by Niger's trachoma program.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prevalence of Genetic Determinants of Macrolide Resistance From Population-based SamplesTime frame: 2 years
  2. Load of Genetic Determinants of Macrolide Resistance From Population-based SamplesTime frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Proctor foundation

    San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.